Jared Kaltwasser

People receiving hypomethylating agent (HMA) therapy spent 33 more days at home than people receiving anthracycline-based therapy in the first year after diagnosis.

A new prevalence study shows more people are living beyond age 65 with type 1 diabetes (T1D).

A Chinese study shows hypertension management led by nonphysicians can be safe and effective.

The most common treatment-related adverse events were injection site reactions, the study found.

There currently are no guidelines on how to treat this patient group, despite a high risk of mortality.

Men are less likely than women to desire community when exercising, the authors found.

The authors said their analysis should help clinicians better monitor patients for potential adverse events.

The coalition said, however, that patient-reported outcomes (PROs) in the myelodysplastic syndrome (MDS) space will be most meaningful if they are collected rigorously and if the data are transparent.

The new data shed light on long-term outcomes for patients receiving duvelisib, although the investigators said the treatment landscape has also shifted significantly since the original trial.

The report found a selective serotonin reuptake inhibitor (SSRI) did not offset the effects of myasthenia gravis (MG) medication.

A new report builds on previous research that could help scientists better understand type 1 diabetes (T1D) risk.

However, investigators said there is some evidence suggesting attention-deficit/hyperactivity disorder may be more common in certain age groups of children with hemophilia.

A 68-year-old man was diagnosed with ocular myasthenia gravis after presenting with double-vision and photophobia.

A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.

A new report says early evidence of using gene therapy to treat monogenic diseases offers reason for optimism.

Patients with type 1 diabetes (T1D) reported improved glucose outcomes, but they also said their sleep and quality of life benefited.

The findings show exercise-induced hypertension increases myocardial oxygen demand.

New therapies are helping patients, but are also driving up overall costs of care.

Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.

COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.

The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.

Only 11 cases of adverse events (AEs) were reported over a 6-year time frame, the investigators found, following administration of chimeric antigen receptor T-cell therapy (CAR T).

The analysis also found the therapy has a manageable safety profile.

The therapy bridges activated factors IX and X to mimic the function of missing or deficient factor VIII.

A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter.

Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia.

Investigators said both reflexology and acupressure led to similar improvement in patients after 4 weeks.

Previous research links type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD).

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).